Immunotherapy for HCV infection: next steps

References

• Thomson BJ, Finch RG. Hepatitis C virus infection. Clin. Microbiol. Infect.11(2), 86–94 (2005).
   Google Scholar
• Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon α. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med.321(22), 1501–1506 (1989).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med.339(21), 1485–1492 (1998).
   PubMed Web of Science ®Google Scholar
• Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro–oesophageal reflux. Aliment Pharmacol. Ther.12(2), 159–165 (1998).
   PubMed Web of Science ®Google Scholar
• Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment – finding the right path. Nat. Rev. Drug Discov.6(12), 991–1000 (2007).
   PubMed Web of Science ®Google Scholar
• Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature436(7053), 946–952 (2005).
   PubMed Web of Science ®Google Scholar
• Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature436(7053), 961–966 (2005).
   PubMed Web of Science ®Google Scholar
• Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut55(9), 1350–1359 (2006).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med.347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Balan V, Nelson DR, Sulkowski MS et al. A Phase I/II study evaluating escalating doses of recombinant human albumin–interferon-α fusion protein in chronic hepatitis C patients who have failed previous interferon-α-based therapy. Antivir. Ther.11(1), 35–45 (2006).
   PubMed Web of Science ®Google Scholar
• Bain VG, Kaita KD, Yoshida EM et al. A Phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin–interferon α fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol.44(4), 671–678 (2006).
   PubMed Web of Science ®Google Scholar
• Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-α species, consensus interferon. J. Interferon Cytokine Res.16(7), 489–499 (1996).
   PubMed Web of Science ®Google Scholar
• Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-α: antiviral, antiproliferative, and natural killer-inducing activities. J. Interferon Res.12(1), 55–59 (1992).
   PubMedGoogle Scholar
• Sjogren MH, Sjogren R, Holtzmuller K et al. Interferon acon-1 and ribavirin versus interferon α-2b and ribavirin in the treatment of chronic hepatitis C. Dig. Dis. Sci.50(4), 727–732 (2005).
   PubMedGoogle Scholar
• Fattovich G, Zagni I, Minola E et al. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J. Hepatol.39(5), 843–849 (2003).
   PubMedGoogle Scholar
• Tong MJ, Reddy KR, Lee WM et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology26(3), 747–754 (1997).
   PubMed Web of Science ®Google Scholar
• Barbaro G, Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon α-2b and ribavirin in combination: an Italian pilot study. Eur. J. Gastroenterol. Hepatol.14(5), 477–483 (2002).
   Google Scholar
• Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon α-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology126(4), 1015–1023; discussion 1947 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gonzalez SA, Ahmed F et al. A randomized trial of pegylated interferon α-2b plus ribavirin in the retreatment of chronic hepatitis C. Am. J. Gastroenterol.100(11), 2453–2462 (2005).
   PubMed Web of Science ®Google Scholar
• Cornberg M, Hadem J, Herrmann E et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J. Hepatol.44(2), 291–301 (2006).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Bacon BR, Gordon SC et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology46(5), 1341–1349 (2007).
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Berg T, Desager JP et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology42(3), 724–731 (2005).
   PubMed Web of Science ®Google Scholar
• Weiner AJ, Paliard X, Selby MJ et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J. Virol.75(15), 7142–7148 (2001).
   Google Scholar
• Bassett SE, Guerra B, Brasky K et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology33(6), 1479–1487 (2001).
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Chavez D et al. Cross-genotype immunity to hepatitis C virus. J. Virol.78(3), 1575–1581 (2004).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Diagnostic tests for hepatitis C. J. Hepatol.31(Suppl. 1), 71–79 (1999).
   PubMed Web of Science ®Google Scholar
• Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science258(5079), 135–140 (1992).
   PubMed Web of Science ®Google Scholar
• Lai ME, Mazzoleni AP, Argiolu F et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet343(8894), 388–390 (1994).
   PubMed Web of Science ®Google Scholar
• Cooper S, Erickson AL, Adams EJ et al. Analysis of a successful immune response against hepatitis C virus. Immunity10(4), 439–449 (1999).
   PubMed Web of Science ®Google Scholar
• Post JJ, Pan Y, Freeman AJ et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J. Infect. Dis.189(10), 1846–1855 (2004).
   PubMed Web of Science ®Google Scholar
• Qureshi SA. Hepatitis C virus – biology, host evasion strategies, and promising new therapies on the horizon. Med. Res. Rev.27(3), 353–373 (2007).
   PubMed Web of Science ®Google Scholar
• Rispeter K, Lu M, Behrens SE, Fumiko C, Yoshida T, Roggendorf M. Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection. Virus Genes21(3), 179–188 (2000).
   Google Scholar
• Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med.191(9), 1499–1512 (2000).
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Jung MC et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology117(4), 933–941 (1999).
   PubMed Web of Science ®Google Scholar
• Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med.194(10), 1395–1406 (2001).
   PubMed Web of Science ®Google Scholar
• Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science302(5645), 659–662 (2003).
   PubMed Web of Science ®Google Scholar
• Shoukry NH, Grakoui A, Houghton M et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med.197(12), 1645–1655 (2003).
   PubMed Web of Science ®Google Scholar
• Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J. Clin. Invest.98(6), 1432–1440 (1996).
   PubMed Web of Science ®Google Scholar
• Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med.1499–1512 (2000).
   Google Scholar
• Lauer GM, Barnes E, Lucas M et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology127(3), 924–936 (2004).
   PubMedGoogle Scholar
• Frese M, Schwarzle V, Barth K et al. Interferon-g inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology35(3), 694–703 (2002).
   PubMedGoogle Scholar
• Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest.98(3), 706–714 (1996).
   PubMed Web of Science ®Google Scholar
• Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet346(8981), 1006–1007 (1995).
   PubMed Web of Science ®Google Scholar
• Day CL, Lauer GM, Robbins GK et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J. Virol.76(24), 12584–12595 (2002).
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl Acad. Sci. USA91(4), 1294–1298 (1994).
   PubMed Web of Science ®Google Scholar
• Youn JW, Park SH, Lavillette D et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology42(6), 1429–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Elmowalid GA, Qiao M, Jeong SH et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA104(20), 8427–8432 (2007).
   PubMed Web of Science ®Google Scholar
• Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med.12(2), 190–197 (2006).
   PubMed Web of Science ®Google Scholar
• Rollier C, Depla E, Drexhage JA et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol.78(1), 187–196 (2004).
   PubMed Web of Science ®Google Scholar
• Capone S, Meola A, Ercole BB et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol.80(4), 1688–1699 (2006).
   PubMed Web of Science ®Google Scholar
• Capone S, Zampaglione I, Vitelli A et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J. Immunol.177(10), 7462–7471 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson DR, Marousis CG, Davis GL et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J. Immunol.158(3), 1473–1481 (1997).
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, He XS, Nascimbeni M et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol.169(6), 3447–3458 (2002).
   PubMed Web of Science ®Google Scholar
• Gruener NH, Lechner F, Jung MC et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J. Virol.75(12), 5550–5558 (2001).
   PubMed Web of Science ®Google Scholar
• Urbani S, Boni C, Missale G et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol.76(24), 12423–12434 (2002).
   PubMed Web of Science ®Google Scholar
• Appay V, Dunbar PR, Callan M et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med.8(4), 379–385 (2002).
   PubMed Web of Science ®Google Scholar
• Rosen HR, Miner C, Sasaki AW et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology35(1), 190–198 (2002).
   PubMed Web of Science ®Google Scholar
• Nevens F, Roskams T, Van Vlierberghe H et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology38(5), 1289–1296 (2003).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Depla E, Hulstaert F et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine22(23–24), 3080–3086 (2004).
   PubMed Web of Science ®Google Scholar
• Schlaphoff V, Klade CS, Jilma B et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine25(37–38), 6793–6806 (2007).
   PubMed Web of Science ®Google Scholar
• Firbas C, Jilma B, Tauber E et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine24(20), 4343–4353 (2006).
   PubMed Web of Science ®Google Scholar
• Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther.6(4), 508–514 (1999).
   PubMed Web of Science ®Google Scholar
• Gronevik E, von Steyern FV, Kalhovde JM, Tjelle TE, Mathiesen I. Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J. Gene Med.7(2), 218–227 (2005).
   PubMed Web of Science ®Google Scholar
• Peng B, Zhao Y, Xu L, Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine25(11), 2064–2073 (2007).
   PubMed Web of Science ®Google Scholar
• Ahlen G, Soderholm J, Tjelle T et al.In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J. Immunol.179(7), 4741–4753 (2007).
   PubMed Web of Science ®Google Scholar
• Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol.82(11), 5643–5649 (2008).
   PubMedGoogle Scholar
• Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine22(8), 991–1000 (2004).
   PubMed Web of Science ®Google Scholar
• Rollier CS, Paranhos-Baccala G, Verschoor EJ et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology45(3), 602–613 (2007).
   PubMed Web of Science ®Google Scholar